| Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up M Ekstedt, H Hagström, P Nasr, M Fredrikson, P Stål, S Kechagias, ... Hepatology 61 (5), 1547-1554, 2015 | 2276 | 2015 |
| Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta‐analysis PS Dulai, S Singh, J Patel, M Soni, LJ Prokop, Z Younossi, G Sebastiani, ... Hepatology 65 (5), 1557-1565, 2017 | 1746 | 2017 |
| Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD H Hagström, P Nasr, M Ekstedt, U Hammar, P Stål, R Hultcrantz, ... Journal of hepatology 67 (6), 1265-1273, 2017 | 969 | 2017 |
| Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis RS Taylor, RJ Taylor, S Bayliss, H Hagström, P Nasr, JM Schattenberg, ... Gastroenterology 158 (6), 1611-1625. e12, 2020 | 782 | 2020 |
| Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long‐term follow‐up study H Hagström, P Nasr, M Ekstedt, U Hammar, P Stål, R Hultcrantz, ... Hepatology communications 2 (1), 48-57, 2018 | 268 | 2018 |
| Natural history of nonalcoholic fatty liver disease: a prospective follow‐up study with serial biopsies P Nasr, S Ignatova, S Kechagias, M Ekstedt Hepatology communications 2 (2), 199-210, 2018 | 154 | 2018 |
| Natural history of NAFLD/NASH M Ekstedt, P Nasr, S Kechagias Current hepatology reports 16, 391-397, 2017 | 136 | 2017 |
| Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events J Boursier, H Hagström, M Ekstedt, C Moreau, M Bonacci, S Cure, ... Journal of Hepatology 76 (5), 1013-1020, 2022 | 113 | 2022 |
| The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease T Hardy, K Wonders, R Younes, GP Aithal, R Aller, M Allison, P Bedossa, ... Contemporary clinical trials 98, 106175, 2020 | 104 | 2020 |
| Cardiovascular risk factors in non‐alcoholic fatty liver disease H Hagström, P Nasr, M Ekstedt, U Hammar, P Stål, J Askling, R Hultcrantz, ... Liver International 39 (1), 197-204, 2019 | 91 | 2019 |
| Accuracy of noninvasive scoring systems in assessing risk of death and liver-related endpoints in patients with nonalcoholic fatty liver disease H Hagström, P Nasr, M Ekstedt, P Stål, R Hultcrantz, S Kechagias Clinical gastroenterology and hepatology 17 (6), 1148-1156. e4, 2019 | 90 | 2019 |
| Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease H Hagström, P Nasr, M Ekstedt, S Kechagias, K Önnerhag, E Nilsson, ... Scandinavian journal of gastroenterology 52 (2), 159-165, 2017 | 86 | 2017 |
| Elevated serum ferritin is associated with increased mortality in non‐alcoholic fatty liver disease after 16 years of follow‐up H Hagström, P Nasr, M Bottai, M Ekstedt, S Kechagias, R Hultcrantz, ... Liver International 36 (11), 1688-1695, 2016 | 84 | 2016 |
| Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta … FE Mózes, JA Lee, Y Vali, O Alzoubi, K Staufer, M Trauner, R Paternostro, ... The Lancet Gastroenterology & Hepatology 8 (8), 704-713, 2023 | 70 | 2023 |
| Using a 3% proton density fat fraction as a cut-off value increases sensitivity of detection of hepatic steatosis, based on results from histopathology analysis P Nasr, MF Forsgren, S Ignatova, N Dahlström, G Cedersund, ... Gastroenterology 153 (1), 53-55. e7, 2017 | 67 | 2017 |
| Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus J Blomdahl, P Nasr, M Ekstedt, S Kechagias Metabolism 115, 154439, 2021 | 56 | 2021 |
| Established and emerging factors affecting the progression of nonalcoholic fatty liver disease S Kechagias, P Nasr, J Blomdahl, M Ekstedt Metabolism 111, 154183, 2020 | 56 | 2020 |
| SAF score and mortality in NAFLD after up to 41 years of follow-up H Hagström, P Nasr, M Ekstedt, S Kechagias, P Stål, P Bedossa, ... Scandinavian journal of gastroenterology 52 (1), 87-91, 2017 | 53 | 2017 |
| The amount of liver fat predicts mortality and development of type 2 diabetes in non‐alcoholic fatty liver disease P Nasr, M Fredrikson, M Ekstedt, S Kechagias Liver International 40 (5), 1069-1078, 2020 | 44 | 2020 |
| Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction Y Shang, P Nasr, M Ekstedt, L Widman, P Stål, R Hultcrantz, S Kechagias, ... JHEP reports 3 (2), 100218, 2021 | 37 | 2021 |
Hannes HagströmKarolinska Institutet在 ki.se 的电子邮件经过验证
